As one of the leading companies in Europe, PentaBase has developed and produced a qPCR assay, specific and sensitive for the analysis of Influenza A, Influenza B, RSV (PAN) and SARS-CoV-2 IP2 (RNA-dependent RNA polymerase) and E (Envelope protein).
Respiratory infections caused by viruses are common and can be very contagious, spreading by coughing, sneezing and contact with contaminated surfaces. A health care professional might have an idea about the cause based on symptoms, season, medical history, or recent travel, but they will not be able to positively diagnose the virus without testing. The ability to efficiently identify infected individuals type of respiratory disease can help limit the spread of the disease and clarifying the patients condition and treatment.
The aim of the respiratory panel is a RT-qPCR assay intended for the detection of nucleic acids from the four most common strains of influenza (B Yamagata, B Victoria, A H1N1 and A H3N2), SARS-CoV-2 and RSV A/B. The different viruses can be found in the liquid from the upper and lower respiratory tracts of infected individuals. Samples can be obtained by nasopharyngeal or oropharyngeal swabs or from saliva. The assay is applicable to standard Real-Time PCR platforms and can be used as a tool to limit the spread of dangerous and contagious respiratory diseases.
Limit the spread of infection and protect your employees
Minimize sick days and maximize productivity
Fast response times and flexible solutions
Possibility for testing of Influenza, RSV and Covid-19 in same test
RespiDetect™ Respiratory Panel 1 RT-qPCR Assay is a semi-quantitative real-time RT (Reverse Transcriptase) quantitative Polymerase Chain Reaction (qPCR) assay, based on PentaBase’s highly sensitive technology, intended for detection of RNA from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza (Inf) and respiratory syncytial virus (RSV) viruses.
RespiDetect™ Respiratory Panel 1 RT-qPCR Assay is a robust assay targeting two viral sequences for the SARS-CoV-2 genome (IP2 and E), two targets for the Inf A H1N1/H3N2 genome (PB1 and PA), Inf B Victoria/Yamagata genome (PB1 and PA) and two targets for RSV A/B genome (named N and P). The assay is provided in a multiplex format, which means that one sample from a patient can be analyzed in one tube.
The RespiDetect™ RT-qPCR Assay is designed to run on open platforms and, currently, it has been validated on BaseTyper™ (PentaBase).
The assay is supplied in either Ready-to-use or Dispense ready formats, and the instrument time required for the analysis is 1,5 hours when using a BaseTyper™.
For purification, we recommend the Viral RNA and DNA purification kit for the BasePurifier™, but other viral purification systems such as one from Biomerieux have also shown to work.
